Berner K, Hernes E, Kvassheim M, Revheim ME, Bastiansen J, Selboe S, Bakken CL, Grønningsæter SR, Bruland ØS, Larsen RH, Bouzelmat L, Jardine VL, Stokke C(2025) First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer J Nucl Med, 66(5), 732-738 DOI 10.2967/jnumed.124.269299, PubMed 40081958
Høyvik AJK, Kvassheim M, Ma LW, Wiig E, Hillestad T, Revheim ME, Liukaityte R, Bruland Ø, Juzeniene A(2025) Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer Eur J Nucl Med Mol Imaging(in press) DOI 10.1007/s00259-025-07330-y, PubMed 40397137
Hompland I, Boye K, Wiedswang AM, Papakonstantinou A, Røsok B, Joensuu H, Bruland Ø(2024) Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study Acta Oncol, 63, 288-293 DOI 10.2340/1651-226X.2024.39851, PubMed 38712513
